The platelet-derived growth factor receptor beta (PDGFRB) is a transmembrane receptor tyrosine kinase crucial for regulating cell proliferation, migration, and survival. It binds ligands like PDGF-BB and PDGF-DD, triggering dimerization and autophosphorylation, which activates downstream signaling pathways (e.g., RAS-MAPK, PI3K-AKT). PDGFRB dysregulation is implicated in cancers, fibrosis, and vascular disorders.
PDGFRB antibodies are essential tools in research and diagnostics. In basic research, they detect receptor expression, activation (via phospho-specific antibodies), and localization in tissues or cultured cells using techniques like Western blot, immunohistochemistry (IHC), or flow cytometry. Clinically, PDGFRB antibodies aid in diagnosing conditions linked to receptor overexpression or mutations, such as certain leukemias or solid tumors. For example, activating PDGFRB mutations (e.g., T681I) or fusion genes (e.g., ETV6-PDGFRB) drive oncogenic signaling in myeloproliferative neoplasms.
Therapeutically, monoclonal antibodies and tyrosine kinase inhibitors (TKIs) targeting PDGFRB, like imatinib or sunitinib, are used to block aberrant signaling in cancers (e.g., gastrointestinal stromal tumors) or hypereosinophilic syndrome. Research-grade antibodies also help validate drug efficacy in preclinical models. However, challenges remain in minimizing off-target effects and resistance mechanisms. Overall, PDGFRB antibodies bridge mechanistic insights, diagnostic precision, and targeted therapies in PDGFRB-associated pathologies.